244 related articles for article (PubMed ID: 32748602)
1. [Preparation and characterization of HBc virus like particles with site-directed coupling function].
Liu D; Li B; Bi C; Qiao H; Wu X
Sheng Wu Gong Cheng Xue Bao; 2020 Jul; 36(7):1440-1449. PubMed ID: 32748602
[TBL] [Abstract][Full Text] [Related]
2. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
[TBL] [Abstract][Full Text] [Related]
3. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
4. The position of Spy Tag/Catcher system in hepatitis B core protein particles affects the immunogenicity and stability of the synthetic vaccine.
Sheng Y; Li Z; Lin X; Ma Y; Ren Y; Su Z; Ma G; Zhang S
Vaccine; 2023 Jul; 41(33):4867-4878. PubMed ID: 37391312
[TBL] [Abstract][Full Text] [Related]
5. Development of HBc virus-like particles as modular nanocarrier by intein-mediated trans-splicing.
Wang Z; Tang S; Yue N; Qian Z; Zhou S
Biochem Biophys Res Commun; 2021 Jan; 534():891-895. PubMed ID: 33213839
[TBL] [Abstract][Full Text] [Related]
6. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Expression of Tandem-HBc Virus-Like Particles (VLPs).
Stephen SL; Beales L; Peyret H; Roe A; Stonehouse NJ; Rowlands DJ
Methods Mol Biol; 2018; 1776():97-123. PubMed ID: 29869237
[TBL] [Abstract][Full Text] [Related]
8. Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications.
Strods A; Ose V; Bogans J; Cielens I; Kalnins G; Radovica I; Kazaks A; Pumpens P; Renhofa R
Sci Rep; 2015 Jun; 5():11639. PubMed ID: 26113394
[TBL] [Abstract][Full Text] [Related]
9. Genetically engineered fusion of allergen and viral-like particle induces a more effective allergen-specific immune response than a combination of them.
Sani MZ; Bargahi A; Momenzadeh N; Dehghani P; Moghadam MV; Maleki SJ; Nabipour I; Shirkani A; Akhtari J; Hesamizadeh K; Heidari S; Omrani F; Akbarzadeh S; Mohammadi M
Appl Microbiol Biotechnol; 2021 Jan; 105(1):77-91. PubMed ID: 33215260
[TBL] [Abstract][Full Text] [Related]
10. The Hepatitis B Virus Core Variants that Expose Foreign C-Terminal Insertions on the Outer Surface of Virus-Like Particles.
Dishlers A; Skrastina D; Renhofa R; Petrovskis I; Ose V; Lieknina I; Jansons J; Pumpens P; Sominskaya I
Mol Biotechnol; 2015 Dec; 57(11-12):1038-49. PubMed ID: 26446016
[TBL] [Abstract][Full Text] [Related]
11. Site-Specific Modification of Virus-Like Particles for Exogenous Tumor Antigen Display and Minimizing Preexisting Immunity.
Cheng K; Ma N; Liang J; Ma X; Feng Q; Liu G; Xu C; Tang M; Zhang L; Gao X; Xu J; Wang C; Zhu F; Wang X; Li X; Zhao X; Nie G
Small; 2023 Jun; 19(23):e2300125. PubMed ID: 36879481
[TBL] [Abstract][Full Text] [Related]
12. In situ bio-mineralized Mn nanoadjuvant enhances anti-influenza immunity of recombinant virus-like particle vaccines.
Sheng Y; Li Z; Lin X; Wang L; Zhu H; Su Z; Zhang S
J Control Release; 2024 Apr; 368():275-289. PubMed ID: 38382812
[TBL] [Abstract][Full Text] [Related]
13. Flagellin/Virus-like Particle Hybrid Platform with High Immunogenicity, Safety, and Versatility for Vaccine Development.
Zhao Y; Li Z; Voyer J; Li Y; Chen X
ACS Appl Mater Interfaces; 2022 May; 14(19):21872-21885. PubMed ID: 35467839
[TBL] [Abstract][Full Text] [Related]
14. A novel rapid modularized hepatitis B core virus-like particle-based platform for personalized cancer vaccine preparation via fixed-point coupling.
Ji M; Zhu J; Xie XX; Liu DQ; Wang B; Yu Z; Liu RT
Nanomedicine; 2020 Aug; 28():102223. PubMed ID: 32422220
[TBL] [Abstract][Full Text] [Related]
15. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
[TBL] [Abstract][Full Text] [Related]
16. Vaccine delivery system for tuberculosis based on nano-sized hepatitis B virus core protein particles.
Dhanasooraj D; Kumar RA; Mundayoor S
Int J Nanomedicine; 2013; 8():835-43. PubMed ID: 23486691
[TBL] [Abstract][Full Text] [Related]
17. Silica nanoparticles as the adjuvant for the immunisation of mice using hepatitis B core virus-like particles.
Skrastina D; Petrovskis I; Lieknina I; Bogans J; Renhofa R; Ose V; Dishlers A; Dekhtyar Y; Pumpens P
PLoS One; 2014; 9(12):e114006. PubMed ID: 25436773
[TBL] [Abstract][Full Text] [Related]
18. Anti-Aβ antibodies induced by Aβ-HBc virus-like particles prevent Aβ aggregation and protect PC12 cells against toxicity of Aβ1-40.
Feng G; Wang W; Qian Y; Jin H
J Neurosci Methods; 2013 Aug; 218(1):48-54. PubMed ID: 23701997
[TBL] [Abstract][Full Text] [Related]
19. A novel combined vaccine based on monochimeric VLP co-displaying multiple conserved epitopes against enterovirus 71 and varicella-zoster virus.
Wu Y; Zhu R; Xu L; Li Y; Li S; Yu H; Li S; Zhu H; Cheng T; Xia N
Vaccine; 2017 May; 35(20):2728-2735. PubMed ID: 28408118
[TBL] [Abstract][Full Text] [Related]
20. Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates.
Kazaks A; Lu IN; Farinelle S; Ramirez A; Crescente V; Blaha B; Ogonah O; Mukhopadhyay T; de Obanos MP; Krimer A; Akopjana I; Bogans J; Ose V; Kirsteina A; Kazaka T; Stonehouse NJ; Rowlands DJ; Muller CP; Tars K; Rosenberg WM
BMC Biotechnol; 2017 Nov; 17(1):79. PubMed ID: 29126399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
